McCluskey Anthony G, Boyd Marie, Gaze Mark N, Mairs Robert J
Targeted Therapy Group & Department of Child Health, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Glasgow G61 1BD, UK.
Cancer Lett. 2005 Oct 18;228(1-2):221-7. doi: 10.1016/j.canlet.2004.11.062.
MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radio-potentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [131I]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [131I]MIBG in vitro.
间碘苄胍（MIBG）可选择性地浓聚于神经母细胞瘤细胞中，放射性碘化MIBG已在靶向放疗中取得了一定成功。然而，长期治愈仍然难以实现，拓扑异构酶I抑制剂拓扑替康可能会改善现有的[131I]MIBG治疗。虽然已有报道称电离辐射与拓扑异构酶I抑制剂联合使用具有协同杀伤作用，但对于最佳给药方案尚无共识。此外，尚未有人尝试证明拓扑异构酶I抑制剂与靶向放疗之间的放射增敏作用。我们正在研究拓扑替康与[131I]MIBG对神经母细胞瘤细胞的各种联合给药方案，初步数据表明拓扑替康在体外可诱导[131I]MIBG的摄取增加。
